The occurrence rate of primary liver cancer in malignant tumors ranks sixth in the world, and the mortality rate ranks third, with a poor prognosis and a five-year survival rate of less than 5%. Most patients with liver cancer in China are found to be in the intermediate and advanced stages, and a targeted immunotherapy combination has become the main treatment option. However, many patients have underlying liver lesions, and their liver function cannot meet the requirements of targeted immunotherapy, which directly affects the treatment of liver cancer patients. Therefore, it is very important to optimize the patient's liver function in a timely manner so as to obtain the opportunity for anti-tumor therapy. This article reviews the current status and response strategies before liver injury related to targeted immune therapy in patients with primary liver cancer.
全球恶性肿瘤中原发性肝癌的发病率居第六位，病死率居第三位，预后差，5年生存率低于5%。在我国，大多数肝癌患者发现时已为中晚期，靶免联合治疗成为主要的治疗方案。然而，不少患者存在肝脏基础病变，肝功能不能满足靶免治疗的要求，直接影响肝癌患者的治疗。因此，及时调整患者的肝功能使其获得抗肿瘤治疗机会，显得非常重要。现就目前原发性肝癌患者靶免治疗前相关肝损伤的现状及应对策略进行综述。.
Keywords: Hepatocellular carcinoma; Liver injury; Liver protection; Target-immunotherapy.